Chronic Lymphocytic Leukemia | Oncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting — Chronic Lymphocytic Leukemia Edition
Research To Practice | Oncology Videos · Dr. Neil Love
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr John Allan, including the following topics:
• Update on key studies of acalabrutinib in the front-line setting (0:00)
• Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11)
• Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06)
• Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08)
• Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49)
• Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22)
• Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15)
• Emerging data with novel Bcl-2 inhibitors (1:11:26)
• Evolving data with subcutaneous epcoritamab for patients with Richter's transformation and CLL (1:14:37)